Physician profile
Sara Baker
NPI 1528682309
$1,594.67
in general payments reported to CMS, 2019-2025
23 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $472 · 2023: $258 · 2024: $302 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.12 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $282.70 | 2021-2024 | |
| Viiv Healthcare Company | $258.69 | 2021-2025 | Apretude |
| Intra-Sana Laboratories | $194.78 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ardelyx, INC. | $121.84 | 2025 | Ibsrela |
| Exact Sciences Corporation | $82.63 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $72.29 | 2021-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $63.01 | 2025 | Breztri |
| Daiichi Sankyo INC. | $58.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.26 | 2021-2022 | |
| Dynavax Technologies Corporation | $48.90 | 2022 | |
| Pfizer INC. | $47.00 | 2021-2025 | |
| Lilly USA, LLC | $44.38 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $44.04 | 2022-2023 | |
| Theratechnologies INC. | $43.13 | 2021 | |
| Janssen Biotech, INC. | $33.57 | 2022-2023 | Symtuza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.39 | 2024 | Aptima |
| Dexcom, INC. | $24.59 | 2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $16.78 | 2024 | Doc Band |
| Alk-Abello, INC | $16.60 | 2025 | Neffy |
| Currax Pharmaceuticals LLC | $16.35 | 2025 | Contrave |
| Phadia US INC. | $14.63 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $14.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.